A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Trial Profile

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CheckMate 063
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Sep 2017 Results of pooled analysis of this trial and three other trials (70036762, 700220443, 700222443) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 02 Aug 2017 Planned End Date changed from 1 Aug 2016 to 30 Dec 2018.
    • 05 Apr 2017 Results of a biomarker analysis assessing soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients with advanced, refractory squamous non-small cell lung cancer treated with nivolumab in CheckMate 063 study, presented at the 108th Annual Meeting of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top